Bispecific antibody binding TRAIL-R2 and CD3
US10813995B2 · kind B2 · utility
0Cited by
2References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 1, 2016 |
| Grant date | Oct 27, 2020 |
| Priority date | — |
| Expiry date | Jan 14, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention concerns the field of cancer immunotherapy, and in particular drugs with low toxicity which can overcome drug-resistance. The present invention concerns novel bispecific antibodies which have the capability of binding both the TRAIL tumor associated antigen and the T lymphocyte CD3. The invention further relates to compositions comprising the bispecific antibodies and a labelling agent, and to pharmaceutical compositions. The present invention also relates to the use of the bispecific antibodies in the treatment of a tumor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.